8-K
Annovis Bio Announces Launch of Proposed Public Offering of Common Stock and Warrants
8-K
Preliminary Cash and Cash Equivalents Estimated at Approximately $2.8 Million as of September 30, 2026
8-K
Annovis Bio Holds Special Meeting and Approves Charter Amendment to Increase Authorized Common Stock
8-K
Annovis Bio Receives NYSE Continued Listing Standard Notice
8-K
Corrected Proxy Statement Discloses 2025 and 2024 Audit Fees of $515,000 and $482,045, Respectively
8-K
Annovis Bio Reports Q2 2026 Financial Results and Clinical Progress for Buntanetap
